Back to news

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

Globe Newswire•17/11/2026•07:00 ET
1

Key Highlights

  • ➤EU approves Libtayo 700 mg every six weeks after initial 12-week regimen
  • ➤Subsequent Libtayo 350 mg infusions may be shortened from 30 to 15 minutes
  • ➤Approval covers all six EU-approved skin, lung and cervical cancer indications
  • ➤U.S. supplemental BLA review ongoing, with decision expected in March 2027

Expert Statements

Israel Lowy, Clinical Development Unit Head, Oncology, at Regeneron

“Managing advanced cancer requires a significant investment of time and energy from patients, caregivers and clinical teams alike”

Israel Lowy, Clinical Development Unit Head, Oncology, at Regeneron

“The European Commission’s approval of this alternate Libtayo dosing regimen reflects our commitment to advancing solutions that can help improve the treatment experience and address the practical challenges of cancer care. By offering an every-six-week maintenance schedule, and potentially halving infusion times for the every-three-week dose, we can help ease the burden of frequent clinic visits and longer infusion times for patients, while giving healthcare providers greater flexibility.”

Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks

Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in